

41. (amended) The method of claim 36, wherein said wild-type packaging signal is from human adenovirus serotype 5.

REMARKS

This is a preliminary amendment; claims 1-41 are pending. The amendments to claims 4, 32 and 41 merely change multiply dependent claims to non-multiply dependent claims. No new matter has been added.

Attached is Appendix 1, showing changes made to each claim.

Applicants assert that all claims are in condition for allowance, and a favorable action on the merits is earnestly solicited.

Respectfully submitted,

By Joanne M. Giesser
Joanne M. Giesser
Reg. No. 32,838
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-3046

Date: August 3, 2001